Halozyme Therapeutics (NEO:HALO) Stock Price Down 0.3%

Alanna Baker 2021-05-09 11:05

Halozyme Therapeutics logo Halozyme Therapeutics, Inc. (NEO:HALO)’s stock price dropped 0.3% during mid-day trading on Friday . The company traded as low as C$47.36 and last traded at C$47.57. Approximately 870,638 shares changed hands during mid-day trading, a decline of 33% from the average daily volume of 1,307,541 shares. The stock had previously closed at C$47.69.

Separately, Fundamental Research lowered their price target on Halozyme Therapeutics from C$0.27 to C$0.24 and set a “top pick” rating on the stock in a research note on Tuesday, April 20th.

The company has a debt-to-equity ratio of 266.21, a current ratio of 1.32 and a quick ratio of 1.11.

Halozyme Therapeutics Company Profile (NEO:HALO)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.